Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly's Keflex patent

Executive Summary

Lilly plans to appeal a New Jersey Federal Court decision that found scope of Lilly's Keflex (cephalexin) patent was not as broad as the company maintained. Lilly filed a patent infringement suit against Vitarine in February. Lilly says the patent in litigation relates to a dense crystalline form of cephalexin, and maintains that the patent does not expire until 1989. The patent covering the cephalexin molecule expired in April.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS011908

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel